Endiatx built a swallowable robotic pill for at-home endoscopies

Anyone who has ever had a traditional endoscopy knows the dread of taking a thick, flexible tube down the throat.

Even with sedation, it means taking a day off, fasting, finding a ride home, and sitting in hospital waiting rooms for hours.

Medical robotics startup Endiatx wants to replace that entire ordeal with a single pill. The California-based company has built PillBot, a remote-controlled capsule robot that lets a doctor examine your stomach while you sit on your couch.

According to reports from VentureBeat, PillBot has already advanced to human clinical trials. Endiatx CEO Torrey Smith stated that pivotal trials are slated to begin at a leading U.S. medical institution in Q3 or Q4, with the ultimate goal of securing FDA approval and commercially launching by early 2026.

A drone inside your gut

PillBot measures just 13mm by 30mm, roughly the size of a multivitamin pill or a pistachio.

While passive capsule cameras have existed for years, PillBot is an active vehicle. Thanks to tiny built-in pumpjet thrusters, the device can swim through stomach fluids much like a multicopter drone maneuvers in the air.

Preparation is refreshingly simple. Patients stay awake, skip food, drink plenty of water to give the robot room to maneuver, and swallow it.

A gastroenterologist anywhere in the world can then steer the robot using a smartphone app. The current prototype streams high-definition video at 2.3 megapixels per second, with plans to quadruple that quality in upcoming iterations.

Once the scan is complete, the robot powers down and naturally exits the body within 6 to 24 hours. Endiatx is also developing AI models to deliver preliminary diagnostic screenings, with hopes of eventually making the pill fully autonomous.

Why it matters

Around 800,000 people worldwide and 11,000 in the U.S. are diagnosed with stomach cancer each year, with far too many cases caught too late simply because patients avoid or lack access to standard endoscopies.

PillBot’s real promise is democratizing preventive care. Turning an invasive hospital visit into an at-home video call could dramatically increase routine screening compliance, especially in rural or underserved areas.

For the healthcare system, offloading routine visual screenings to remote pills frees up precious operating rooms, nursing staff, and anesthesiologists for acute surgical cases.

We think Endiatx made a very clever architectural decision by starting with passive diagnostic observation rather than trying to cut or biopsy tissue on day one. By proving mobility and wireless transmission first, they lower the initial regulatory and mechanical hurdles.

That said, swallowing an active mechanical machine with spinning thrusters and a battery is a huge psychological and regulatory leap. Proving that it cannot cause mucosal injury, leak, or get lodged inside a patient will be the deciding factor in whether the FDA signs off by 2026.